M&A

M&A

Lupin to acquires 9 brands from Bausch Health in Brazil

Press Release  

Publicly listed, Mumbai-based Lupin, via its wholly owned subsidiary in Brazil (MedQuímica), is to acquire all rights to nine medicines for use in the Brazilian market from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc. As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson's disease.